美国MITBBS

Key takeaway: Adding the personalized mRNA vaccine (intismeran) to Keytruda (pembrolizumab) improves recurrence‑free survival, distant metastasis‑free survival, and overall survival compared with Keytruda alone in high‑risk resected melanoma. The quantitative data come from 5‑year follow‑up of the KEYNOTE‑942 trial.

---

Survival & Recurrence Outcomes

1. Recurrence‑Free Survival (RFS)

• Combination (Keytruda + mRNA vaccine):
  49% reduction in risk of recurrence or death vs Keytruda alone (HR ≈ 0.51). Merck
• Keytruda alone:
  Higher recurrence risk; median RFS shorter. oncodaily.com

2. Distant Metastasis‑Free Survival (DMFS)

• Combination therapy:
  59% reduction in risk of distant metastasis or death (HR ≈ 0.41). Merck
• Keytruda alone:
  Significantly worse DMFS outcomes. Cancer Network

3. Overall Survival (OS)

• Combination therapy:
  92.2% 5‑year overall survival. PR Newswire
• Keytruda alone:
  71.3% 5‑year overall survival. PR Newswire

---

What This Means Clinically

The mRNA vaccine intismeran is personalized to each patient’s tumor mutations. When combined with Keytruda:

• It strengthens T‑cell responses against melanoma.
• It reduces recurrence, prevents spread, and improves long‑term survival.
• Benefits are durable for at least 5 years, with no new safety concerns. ASCO Publications

---

Comparison Table

Treatment	5‑Year Overall Survival	Recurrence Risk Reduction	Distant Metastasis Risk Reduction
Keytruda + mRNA vaccine	92.2% PR Newswire	49% Merck	59% Merck
Keytruda alone	71.3% PR Newswire	Baseline	Baseline

---

摘要

将个体化 mRNA 疫苗（intismeran） 与 Keytruda（帕博利珠单抗） 联合使用，相比单用 Keytruda，可提高 无复发生存率、远处转移无病生存率以及总体生存率。有关数据来自 KEYNOTE‑942 试验的 5 年随访。

---

生存与复发结果

1. 无复发生存率（RFS）

• 联合治疗（Keytruda + mRNA 疫苗）：
  复发或死亡风险降低 49%（风险比 HR ≈ 0.51）。
• 单用 Keytruda：
  复发风险更高；中位 RFS 更短。

2. 远处转移无病生存率（DMFS）

• 联合治疗：
  远处转移或死亡风险降低 59%（HR ≈ 0.41）。
• 单用 Keytruda：
  DMFS 明显较差。

3. 总体生存率（OS）

• 联合治疗：
  5 年总体生存率 92.2%。
• 单用 Keytruda：
  5 年总体生存率 71.3%。

---

临床意义

个体化 mRNA 疫苗 intismeran 根据患者肿瘤突变定制。与 Keytruda 联合时：

• 增强 T 细胞对黑色素瘤的免疫反应
• 降低复发率
• 减少远处转移
• 提高长期生存率
• 效果 至少维持 5 年，且未发现新的安全性问题

---

对比表

治疗方式	5 年总体生存率	复发风险降低	远处转移风险降低
Keytruda + mRNA 疫苗	92.2%	49%	59%
Keytruda 单药	71.3%	基线	基线

黑色素瘤 mRNA 疫苗能提高患者生存期。患者手术后如果只用 Keytruda 单抗的话，5年存活期是71.3%；如果再加上mRNA 疫苗的话，5年存活请提高到 92.2%。具有统计学上的显著意义。

但黑色素瘤最根本最有效的治疗是早期诊断发现与手术切除。Keytruda 单抗治疗、mRNA 疫苗等只不过是锦上添花的作用。

---

Key takeaway: After complete surgical removal of melanoma, adding Keytruda (pembrolizumab) markedly improves recurrence‑free survival (RFS) and overall survival (OS) compared with surgery alone. The strongest evidence comes from large randomized trials in stage III melanoma.

---

Survival: Surgery Alone vs Surgery + Keytruda

1. Stage III melanoma (post‑surgery adjuvant therapy)

The KEYNOTE‑054 / EORTC 1325‑MG phase III trial compared pembrolizumab vs placebo after complete resection of high‑risk stage III melanoma.

• Pembrolizumab (Keytruda) after surgery

  • Significantly improves recurrence‑free survival at 5 years.
  • Hazard ratio for recurrence or death ≈ 0.61, meaning a 39% reduction in risk vs surgery alone (placebo).
  • This is the definitive evidence base for adjuvant Keytruda.
    Annals of Oncology

• Surgery alone (placebo)

  • Higher recurrence rates.
  • Lower long‑term survival compared with pembrolizumab.

2. Real‑world survival impact (stage III)

A 2024 analysis of resected stage III melanoma in the checkpoint‑therapy era found:

• Post‑operative immunotherapy (including pembrolizumab) significantly improves survival compared with surgery alone.
  ScienceDirect

3. Neoadjuvant + adjuvant Keytruda vs adjuvant only

Although not directly “surgery alone,” this trial shows the magnitude of pembrolizumab’s benefit:

• Event‑free survival at 2 years:
  • 72% with neoadjuvant + adjuvant Keytruda
  • 49% with adjuvant Keytruda alone
    (Surgery‑only outcomes are substantially worse than either.)
    AJMC

---

Summary Table

Treatment	Recurrence‑Free Survival	Overall Survival	Evidence
Surgery alone	Lowest; high recurrence risk	Lower long‑term survival	KEYNOTE‑054 placebo arm Annals of Oncology
Surgery + Keytruda	40% reduction in recurrence risk	Significantly improved OS	KEYNOTE‑054; real‑world stage III data Annals of Oncology ScienceDirect

---

Clinical meaning

• Surgery alone cures many early melanomas, but stage II–III disease has substantial recurrence risk.
• Adding Keytruda activates anti‑tumor immunity, reducing recurrence and improving survival.
• For high‑risk stage II, stage III, and selected stage IIB/IIC patients, Keytruda is now standard of care after surgery.

---

摘要：

在黑色素瘤完成手术切除后，加入 Keytruda（帕博利珠单抗）治疗，相比单纯手术，能显著提高无复发生存率（RFS）和总体生存率（OS）。最强证据来自针对 III 期黑色素瘤的大型随机临床试验。

---

生存率：单纯手术 vs 手术 + Keytruda

1. III 期黑色素瘤（术后辅助治疗）

III 期高风险黑色素瘤的关键试验 KEYNOTE‑054 / EORTC 1325‑MG 比较了术后使用帕博利珠单抗 vs 安慰剂。

• 手术后使用 Keytruda（帕博利珠单抗）

  • 显著提高 5 年无复发生存率
  • 复发或死亡的风险比约为 0.61，即风险降低 39%
  • 这是 Keytruda 作为辅助治疗的核心证据

• 单纯手术（安慰剂组）

  • 复发率更高
  • 长期生存率低于 Keytruda 组

2. 真实世界数据（III 期）

2024 年对切除后的 III 期黑色素瘤分析显示：

• 术后免疫治疗（包括帕博利珠单抗）显著提高生存率
• 单纯手术的长期预后明显较差

3. 术前 + 术后 Keytruda vs 单纯术后 Keytruda

虽然不是“单纯手术”的直接比较，但能展示 Keytruda 的治疗幅度：

• 2 年事件无生存率（EFS）：
  • 72%：术前 + 术后 Keytruda
  • 49%：仅术后 Keytruda
    （单纯手术的结果远低于上述任何一种方案。）

---

总结表格

治疗方式	无复发生存率（RFS）	总体生存率（OS）	证据来源
单纯手术	最低；复发风险高	长期生存率较低	KEYNOTE‑054 安慰剂组
手术 + Keytruda	复发风险降低约 40%	OS 明显改善	KEYNOTE‑054；真实世界 III 期数据

---

临床意义

• 单纯手术可治愈许多早期黑色素瘤，但 II 期–III 期复发风险显著。
• 加入 Keytruda可激活抗肿瘤免疫，降低复发并提高生存。
• 对于 高风险 II 期、III 期以及部分 IIB/IIC 期患者，Keytruda 已成为术后标准治疗之一。

Modrna 的黑色素瘤 mRNA 疫苗仅仅起辅助治疗作用，目前没有任何关于该疫苗单独使用的临床试验或相关数据。

Moderna/Merck’s personalized mRNA vaccine (intismeran, V940/mRNA‑4157) has been tested after complete surgical resection, in combination with Keytruda, and has shown significant improvement in recurrence‑free survival versus Keytruda alone.

There are no survival data for melanoma patients treated only with an mRNA vaccine, without surgery and without antibody (checkpoint) therapy.

黑色素瘤 mRNA 疫苗是如何起作用的？

Key takeaway: The melanoma mRNA vaccine (such as intismeran/mRNA‑4157) targets patient‑specific tumor neoantigens — mutated proteins that appear only on melanoma cells and not on healthy tissue. These neoantigens act as the “address labels” that direct T cells precisely to the cancer. NDTV Profit Merck

---

What the vaccine actually targets

• Tumor neoantigens — abnormal proteins created by somatic mutations in melanoma cells. These mutations change the amino‑acid sequence of proteins, producing new antigens that the immune system has never seen before. NDTV Profit
• Patient‑specific mutations — intismeran is individualized: each dose encodes up to 34 neoantigens selected from the patient’s own tumor sequencing. intismeranautogene.ai
• MHC-presented peptides — once the mRNA is delivered, cells translate the neoantigen sequences and present them on MHC class I (primarily) to activate CD8⁺ cytotoxic T cells, and sometimes on MHC class II to activate CD4⁺ helper T cells. Frontiers

---

Why neoantigens are ideal targets

• They are unique to the tumor, minimizing off‑target toxicity.
• Melanoma has a high mutational burden, producing many strong neoantigens — making it one of the best cancers for this strategy. Frontiers
• Neoantigen vaccines train the immune system to recognize these mutated peptides and attack any melanoma cell displaying them. NDTV Profit

---

How the targeting works (mechanistically)

1. Tumor biopsy → sequencing identifies somatic mutations.
2. Algorithm selects the most immunogenic neoantigens.
3. A single mRNA construct encoding these neoantigens is manufactured.
4. After injection, host cells express these neoantigens.
5. Immune system sees them as foreign → activates T cells → hunts melanoma cells presenting the same neoantigens. Merck

---

Summary table

Target	What it is	Why it works in melanoma
Neoantigens	Mutated tumor‑specific peptides	Highly abundant in melanoma; absent in normal cells
Somatic mutations	DNA changes unique to the tumor	Provide individualized “fingerprints” for targeting
MHC-presented peptides	Antigen fragments shown to T cells	Enable precise CD8⁺ and CD4⁺ activation

---

摘要：

黑色素瘤 mRNA 疫苗（如 intismeran / mRNA‑4157）的靶点是 患者特异性的肿瘤新抗原（neoantigens）——这些是只出现在黑色素瘤细胞上的突变蛋白，而不会出现在正常组织中。新抗原就像“地址标签”，指导 T 细胞精准攻击肿瘤。

---

疫苗实际靶向的是什么

• 肿瘤新抗原 ——由黑色素瘤细胞的体细胞突变产生的异常蛋白片段。
• 患者特异性突变 ——intismeran 是个体化疫苗：每剂包含 最多 34 个新抗原，来源于患者自身肿瘤测序。
• MHC 呈递的肽段 ——mRNA 进入细胞后被翻译成新抗原，并通过 MHC I 类（主要）呈递给 CD8⁺ 细胞毒性 T 细胞，部分也通过 MHC II 类 激活 CD4⁺ 辅助 T 细胞。

---

为什么新抗原是理想靶点

• 只存在于肿瘤，几乎没有脱靶风险。
• 黑色素瘤具有 极高的突变负荷，产生大量强免疫原性的新抗原。
• 新抗原疫苗能 训练免疫系统 识别这些突变肽段，从而攻击所有呈递相同新抗原的黑色素瘤细胞。

---

靶向机制如何运作

1. 肿瘤活检 → 基因测序识别体细胞突变
2. 算法筛选最具免疫原性的新抗原
3. 制备包含这些新抗原序列的单一 mRNA 构建体
4. 注射后，宿主细胞表达这些新抗原
5. 免疫系统将其视为“外来” → 激活 T 细胞 → 定向杀伤呈递相同新抗原的黑色素瘤细胞

---

总结表格

靶点	是什么	为何适用于黑色素瘤
新抗原	肿瘤特异性突变肽段	黑色素瘤突变多；正常细胞无此抗原
体细胞突变	肿瘤独有的 DNA 改变	提供个体化“指纹”用于靶向
MHC 呈递肽段	呈递给 T 细胞的抗原片段	激活 CD8⁺ 与 CD4⁺ T 细胞，实现精准免疫攻击